Broadleaf Partners’s Amgen AMGN Stock Holding History

Broadleaf Partners’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,970	Closed	-$2.43M	–	53
2017 Q4	$2.43M	Buy	+13,970	New	+$2.47M	2.02%	25

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Broadleaf Partners's AMGN Position: Q1 2018 in Review

Broadleaf Partners sold out of Amgen (AMGN) in Q1 2018, closing a stake of 13,970 shares — an estimated $2.43M sold.

Broadleaf Partners first reported a position in AMGN in Q4 2017 and held it in 1 quarter. The position peaked at $2.43M in Q4 2017. 1,749 funds tracked by Wall St. Rank hold AMGN as of Q1 2018.

Broadleaf Partners reported no remaining Amgen position as of Q1 2018 after selling out during the quarter.
Broadleaf Partners sold 13,970 Amgen shares in Q1 2018, an estimated $2.43M.
Broadleaf Partners first reported a position in Amgen in Q4 2017 and held it in 1 quarter.
Broadleaf Partners's Amgen position peaked at $2.43M in Q4 2017.
1,749 funds tracked by Wall St. Rank held Amgen as of Q1 2018.

Based on Broadleaf Partners's 13F filing for Q1 2018, filed 20 Apr 2018.